GSK plc (GSK) Form 6-K — Oct 26, 2026
GSK announced updated phase Ib BEHOLD-1 data for mocertatug rezetecan (Mo-Rez), a B7-H4-targeted ADC, showing a 62% confirmed objective response rate and 12.2-month median duration of response in platinum-resistant ovarian cancer at the selected phase III dose of 5.8 mg/kg. Median progression-free survival reached 11.1 months in a setting with limited treatment options, and the safety profile remained manageable with grade 3+ treatment-related adverse events in 71% of patients but discontinuation in only 2%.
Key figures
- Phase3 dose
- 5.8 mg/kg
- Median pfs months
- 11.1
- Ild pneumonitis rate
- 2% (n=1/45)
- Grade 3plus trae rate
- 71% (n=32/45)
- Drug to antibody ratio
- 6
- Proc patients enrolled
- 136
- Discontinuation due to trae
- 2% (n=1/45)
- Pivotal phase3 trials underway
- 5
- Confirmed objective response rate
- 62% (n=28/45)
- Median duration of response months
- 12.2
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.